Spruce Biosciences Inc. (SPRB) News
Filter SPRB News Items
SPRB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SPRB News From Around the Web
Below are the latest news stories about SPRUCE BIOSCIENCES INC that investors may wish to consider to help them evaluate SPRB as an investment opportunity.
Spruce Biosciences (SPRB) Upgraded to Buy: Here's WhySpruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic DisorderOn Tuesday, Spruce Biosciences, Inc. (NASDAQ:SPRB) revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. Congenital adrenal hyperplasia (CAH) is a genetic disease that affects the adrenal glands and prevents the production of hormones like cortisol, aldosterone, and androgens. Also Read: Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disord |
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAHSOUTH SAN FRANCISCO, Calif., December 10, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. |
Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSpruce Biosciences ( NASDAQ:SPRB ) Third Quarter 2024 Results Key Financial Results Revenue: US$602.0k (down 80% from... |
Spruce Biosciences Reports Q3 2024 Earnings and UpdatesSpruce Biosciences, Inc. ( (SPRB) ) has released its Q3 earnings. Here is a breakdown of the information Spruce Biosciences, Inc. presented to its investors. Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focusing on developing and commercializing novel therapies for endocrine and neurological disorders, with a key focus on congenital adrenal hyperplasia (CAH). In their third-quarter 2024 earnings report, Spruce Biosciences highlighted upcoming data releases from significant |
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue EstimatesSpruce Biosciences (SPRB) delivered earnings and revenue surprises of 22.22% and 66.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif., November 11, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates. |
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation ConferenceSOUTH SAN FRANCISCO, Calif., October 28, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET. |
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSOUTH SAN FRANCISCO, Calif., September 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 p.m. ET. |
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue EstimatesSpruce Biosciences (SPRB) delivered earnings and revenue surprises of 33.33% and 3.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? |